Cabaletta Bio Dirección
Dirección controles de criterios 2/4
El CEO de Cabaletta Bio's es Steven Nichtberger , nombrado en Jan 2017, tiene una permanencia de 7.25 años. compensación anual total es $1.81M, compuesta por 31.4% salario y 68.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.8% de las acciones de la empresa, por valor de $16.44M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 4.3 años, respectivamente.
Información clave
Steven Nichtberger
Chief Executive Officer (CEO)
US$4.8m
Compensación total
| Porcentaje del salario del CEO | 12.4% |
| Permanencia del CEO | 7.3yrs |
| Participación del CEO | 2.8% |
| Permanencia media de la dirección | 4.9yrs |
| Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
May 22
Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Jan 31Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Dec 28Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Sep 12Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Jun 04Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Oct 20We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Jul 07Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Mar 24We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 09We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
Aug 05Cabaletta Bio EPS beats by $0.08
May 03Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Apr 12What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?
Feb 19
Chardan Capital initiates Cabaletta Bio with Buy rating
Jan 08We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 28Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder
Dec 09Cabaletta Bio +5% on Q3 results, pipeline update
Nov 10Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$5m | US$597k | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$57m |
| Mar 31 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$2m | US$569k | -US$53m |
| Sep 30 2022 | n/a | n/a | -US$51m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$50m |
| Dec 31 2021 | US$4m | US$542k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$42m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$36m |
| Dec 31 2020 | US$4m | US$516k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$29m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$1m | US$437k | -US$22m |
| Sep 30 2019 | n/a | n/a | -US$19m |
| Jun 30 2019 | n/a | n/a | -US$23m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | US$1m | US$213k | -US$12m |
Compensación vs. Mercado: La compensación total de Steven($USD4.81M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.41M).
Compensación vs. Ingresos: La compensación de Steven ha aumentado mientras la empresa no es rentable.
CEO
Steven Nichtberger (62 yo)
7.3yrs
Permanencia
US$4,808,279
Compensación
Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 7.3yrs | US$4.81m | 2.8% $ 14.7m | |
| President of Science & Technology | 5.3yrs | US$2.34m | 0.041% $ 218.4k | |
| Chief Medical Officer | 4.9yrs | US$2.10m | 0% $ 0 | |
| Co-Founder & Co-Chair of Scientific Advisory Board | no data | sin datos | sin datos | |
| Co-Founder & Co-Chair of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chief Financial Officer | 5.3yrs | US$1.53m | 0.10% $ 546.0k | |
| Chief Scientific Officer | 2.5yrs | sin datos | sin datos | |
| General Counsel & Secretary | 2.7yrs | sin datos | sin datos | |
| Chief Compliance Officer | 2.5yrs | sin datos | sin datos | |
| Chief Human Resources Officer | 5.2yrs | sin datos | sin datos | |
| Chief Business Officer | 2.3yrs | sin datos | sin datos |
4.9yrs
Permanencia media
46.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CABA se considera experimentado (4.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 7.3yrs | US$4.81m | 2.8% $ 14.7m | |
| Co-Founder & Co-Chair of Scientific Advisory Board | no data | sin datos | sin datos | |
| Co-Founder & Co-Chair of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.3yrs | US$259.20k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.8yrs | sin datos | sin datos | |
| Independent Director | 5.6yrs | US$260.15k | 0.30% $ 1.6m | |
| Member of Scientific Advisory Board | 2.9yrs | US$202.24k | sin datos | |
| Independent Director | 2.9yrs | US$255.83k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.4yrs | sin datos | sin datos | |
| Independent Director | 5.1yrs | US$255.43k | 0.0021% $ 10.9k |
4.3yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de CABA se considera experimentada (4.3 años de antigüedad promedio).